Effect of individual fc methionine oxidation on FcRn binding: Met252 oxidation impairs fcrn binding more profoundly than Met428 oxidation

Journal of Pharmaceutical Sciences

Volumn 104, Issue 2, 2015, Pages 368-377

  Gao, Xuan ^a   Ji, Junyan A ^a   Veeravalli, Karthik ^a   Wang, Y John ^a   Zhang, Taylor ^a   McGreevy, William ^a   Zheng, Kai ^a   Kelley, Robert F ^a   Laird, Michael W ^a   Liu, Jun ^a   Cromwell, Mary ^a  

^a GENENTECH INC   (United States)

Author keywords

Calorimetry; Critical quality attributes; HPLC; Monoclonal antibody; Neonatal Fc receptor; Oxidation; Protein binding; Serum half life; Stability; Surface plasmon resonance

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN FC FRAGMENT; METHIONINE; PROTEIN A; FC RECEPTOR, NEONATAL; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN G;

ARTICLE; GENE; GENE MUTATION; IMMUNOGLOBULIN G1 GENE; OXIDATION; PROTEIN BINDING; PROTEIN STABILITY; SITE DIRECTED MUTAGENESIS; THERMOSTABILITY; BINDING SITE; CHEMISTRY; HUMAN; METABOLISM; OXIDATION REDUCTION REACTION; SURFACE PLASMON RESONANCE;

BINDING SITES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; METHIONINE; OXIDATION-REDUCTION; RECEPTORS, FC; SURFACE PLASMON RESONANCE;

EID: 84922880581     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24136     Document Type: Article

References (31)

1. Chan AC, Carter PJ. 2010. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 10(5):301-316.
2. Carter PJ. 2006. Potent antibody therapeutics by design. Nat Rev Immunol 6(5):343-357.
3. Morell A, Terry WD, Waldmann TA. 1970. Metabolic properties of IgG subclasses in man. J Clin Invest 49:673-680.
4. Martin WL, West AP Jr., Gan L., Bjorkman PJ. 2001. Crystal structure at 2.8 Å of an FcRn/heterodimeric Fc complex: Mechanism of pH-dependent binding. Mol Cell 7(4):867-877.
5. Junghans RP, Anderson CL. 1996. The protection receptor for IgG catabolism is the β2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci USA 93:5512-5516.
6. Lin YS, Nguyen C, Mendoza J., Escandon E, Fei D, Meng Y.G., Modi NB. 1999. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288:371-378.
7. Gaudreault J, Fei D, Rusit J., Suboc P, Shiu V. 2005. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 46(2):726-733.
8. Suzuki T, Ishii-Watabe A, Tada M., Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, Yamaguchi T. 2010. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the fc domain of human IgG1: A comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol 184(4):1968-1976.
9. Tabrizi MA, Tseng CL, Roskos LK. 2006. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 11:81-88.
10. Bertolotti-Ciarlet A, Wang W, Lownes R., Pristatsky P, Fang Y, McKelvey T., Li Y, Drummond J, Prueksaritanont T, Vlasak J. 2009. Impact of methionine oxidation on the binding of human IgG1 to Fc Rn and Fc gamma receptors. Mol Immunol 46(8-9):1878-1882.
11. Kroon DJ, Baldwin-Ferro A, Lalan P. 1992. Identification of sites of degradation in a therapeutic monoclonal antibody by peptide mapping. Pharm Res 9(11):1386-1393.
12. Wang W, Vlasak J, Li Y., Pristatsky P, Fang Y, Pittman T., Roman J, Wang Y, Prueksaritanont T, Ionescu R. 2011. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies. Mol Immunol 48(6-7):860-866.
13. Pan H, Chen K, Chu L., Kinderman F, Apostol I, Huang G. 2009. Methionine oxidation in human IgG2 Fc decreases binding affinities to protein A and FcRn. Protein Sci 18(2):424-433.
14. Kabat E, Wu T, Perry H., Gottesman K, Foeller C. 1991. Sequences of proteins of immunological interest, 5th edition. Washington, DC: Public Health Service, NIH Publication No. 91-3242.
15. Gaza-Bulseco G, Faldu S, Hurkmans K., Chumsae C, Liu H. 2008. Effect of methionine oxidation of a recombinant monoclonal antibody on the binding affinity to protein A and protein G. J Chromatogr B Analyt Technol Biomed Life Sci 870(1):55-62.
16. Liu D, Ren D, Huang H., Dankberg J, Rosenfeld R, Cocco M.J., Li L., Brems DN, Remmele Jr. RL, 2008. Structure and stability changes of human IgG1Fcasaconsequenceofmethionine oxidation. Biochemistry 47(18):5088-5100.
17. Burmeister WP, Huber AH, Bjorkman PJ. 1994. Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature 372(6504):379-383.
18. Yeung YA, Leabman MK, Marvin J.S., Qiu J., Adams CW, Lien S, Starovasnik MA, Lowman HB. 2009. Engineering human IgG1 affinity to human neonatal Fc receptor: Impact of affinity improvement on pharmacokinetics in primates. J Immunol 182(12):7663-7671.
19. Roopenian DC, Akilesh S. 2007. FcRn: The neonatal Fc receptor comes of age. Nat Rev Immunol 7(9):715-725.
20. + channels. J Physiol 571(Pt 2):329-348.
21. Shao B, Cavigiolio G, Brot N., Oda MN, Heinecke JW. 2008. Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I. Proc Natl Acad Sci USA 105(34):12224-12229.
22. Klein JC, Moen RJ, Smith E.A., Titus MA, Thomas DD. 2011. Structural and functional impact of site-directed methionine oxidation in myosin. Biochemistry 50(47):10318-10327.
23. Ionescu RM, Vlasak J, Price C., Kirchmeier M. 2008. Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. J Pharm Sci 97(4):1414-1426.
24. Deisenhofer J. 1981. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. Biochemistry 20(9):2361-2370.
25. Loew C, Knoblich C, Fichtl J., Alt N, Diepold K, Bulau P., Goldbach P, Adler M, Mahler HC, Grauschopf U. 2012. Analytical protein a chromatography as a quantitative tool for the screening of methionine oxidation in monoclonal antibodies. J Pharm Sci 101(11):4248-4257.
26. West Jr AP, Bjorkman PJ. 2000. Crystal structure and immunoglob-ulin G binding properties of the human major histocompatibility complex-related Fc receptor. Biochemistry 39(32):9698-708.
27. Black SD, Mould DR. 1991. Development of hydrophobicity parameters to analyze proteins which bear post- or cotranslational modifications. Anal Biochem 193(1):72-82.
28. Balog EM, Norton LE, Bloomquist R.A., Cornea RL, Black DJ, Louis CF, Thomas D.D., Fruen BR. 2003. Calmodulin oxidation and me-thionine to glutamine substitutions reveal methionine residues critical for functional interaction with ryanodine receptor-1. J Biol Chem 278(18):15615-15621.
29. Chin D, Means AR. 1996. Methionine to glutamine substitutions in the C-terminal domain of calmodulin impair the activation of three protein kinases. J Biol Chem 271(48):30465-30471.
30. Chin D, Winkler KE, Means AR. 1997. Characterization of substrate phosphorylation and use of calmodulin mutants to address implications from the enzyme crystal structure of calmodulin-dependent protein kinase I. J Biol Chem 272(50):31235-31240.
31. Yin D, Sun H, Weaver R.F., Squier TC. 1999. Nonessential role for methionines in the productive association between calmodulin and the plasma membrane Ca-ATPase. Biochemistry 38(41):13654-13660.